Autopsy report · NCT04199351

Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

“Amgen determined the totality of the data does not support continuation of AMG 171 development program for treatment of Obesity. No safety concerns identified.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 9 months before it stopped.
• 60 participants enrolled.
• Results were posted on the registry 3 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Amgen

Sponsor type

Industry

Conditions

Obesity

Interventions

AMG 171; Placebo

Participants

60

Sites

3

Countries

United States

Trials that died the same way

• An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED)
  “The overall profile does not support development for obesity” (57% match in meaning)
• Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
  “AMGEN, due to a change in priorities within the Tarlatamab programme, has decided to withdraw its support for the study, which means the clinical trial will be terminated early.” (57% match in meaning)
• Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
  “Amgen decided to terminate the study early to be able to meet US regulatory timelines fo filing. Subjects in treatment were rolled over to the 20140159 study.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.